Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience
Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 627-635
DOI: 10.1002/ccd.70693 ↗At a glance
Vergleichsstudie in Catheterization and Cardiovascular Interventions, published online on 2026-06-12. Written by Marco Tagliafierro and 14 co-authors. Institution: Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA. Major MEDLINE topics: Bioprosthesis, Heart Valve Prosthesis, Aortic Valve, Reoperation. 24 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Bioprosthetic aortic valves require reinterventions once they degenerate. Options include redo‐surgical aortic valve replacement (redoSAVR) and Valve‐in‐Valve transcatheter aortic valve replacement (ViV). Women with valvular disease have historically demonstrated higher procedural risks and worse outcomes compared to men. There is a knowledge gap regarding outcomes of aortic valve reinterventions in women.
Aims
We sought to compare outcomes of ViV versus redoSAVR in women with degenerated bioprosthetic surgical valves.
Methods
Consecutive female patients with prior SAVR undergoing isolated ViV or redoSAVR between 2015 and 2025 were included. Primary endpoints were 30‐day all‐cause mortality, stroke, and major adverse cardiac events (MACE). Secondary (1‐year) endpoints included mortality, stroke, MACE, pacemaker implantation, and cardiac rehospitalization. Propensity score matching (PSM), Cox regression for survival, and Kaplan‐Meier for MACE were performed.
Results
Forty redoSAVR and 92 ViV female patients were included. ViV females were older, had lower BMI, and higher STS‐PROM. Primary endpoints were not significantly different between ViV and redoSAVR: mortality 1 (1.1%) versus 1 (2.5%), p = 0.303; stroke 3 (3.3%) versus 2 (5.0%), p = 0.480; MACE 3 (3.3%) versus 3 (7.5%), p = 0.272. 1‐year endpoints were also comparable: mortality 8 (8.7%) versus 3 (7.5%), p = 0.867; stroke 4 (4.3%) versus 2 (5.0%), p = 0.834; MACE 11 (12.0%) versus 5 (12.5%), p = 0.888; pacemaker 3 (3.3%) versus 1 (2.5%), p = 0.792; rehospitalization 10 (10.9%) versus 2 (5.0%), p = 0.265). Results were consistent before and after PSM.
Conclusions
ViV and redoSAVR in women yielded similar short‐term outcomes. Both represent valid options for treatment of degenerated aortic bioprosthesis.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.
- Department of Surgery, Center for Innovation and Outcomes Research, Columbia University, New York, New York, USA.
- Department of Medicine, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.
ORCID profiles: Marco Tagliafierro
Cite
APA
Tagliafierro, M., Kanade, R., Kirilina, D., Soliman, F., Anzai, I., Kodali, S., Vahl, T., Hahn, R., Nazif, T., Geirsson, A., Takayama, H., Argenziano, M., Kurlansky, P., George, I., & Pirelli, L. (2026). Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions, 108(2), 627-635. https://doi.org/10.1002/ccd.70693
Vancouver
Tagliafierro M, Kanade R, Kirilina D, Soliman F, Anzai I, Kodali S, et al. Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions. 2026;108(2):627-635. doi:10.1002/ccd.70693
BibTeX
@article{Tagliafierro2026,
author = {Tagliafierro, Marco and Kanade, Rahul and Kirilina, Darina and Soliman, Fady and Anzai, Isao and Kodali, Susheel and Vahl, Torsten and Hahn, Rebecca and Nazif, Tamim and Geirsson, Arnar and Takayama, Hiroo and Argenziano, Michael and Kurlansky, Paul and George, Isaac and Pirelli, Luigi},
title = {Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {108},
number = {2},
pages = {627--635},
doi = {10.1002/ccd.70693}
}
EUVIMED